Abstract
RNA amplification tests sensitively detect SARS-CoV-2 infection, but their complexity and cost are prohibitive for expanding COVID-19 testing. We developed “Harmony COVID-19”, a point-of-care test using inexpensive consumables, ready-to-use reagents, and a simple device accommodating up to 4 samples simultaneously. Our ready-to-use, multiplexed reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) can detect down to 0.38 SARS-CoV-2 RNA copies/µL and can report in 17 min for high viral load samples (5,000 copies/µL). Harmony detected 97% or 83% of contrived samples with ≥0.5 viral particles/µL in nasal matrix or saliva, respectively. Evaluation in clinical nasal specimens in viral transport media (VTM, n=101) showed 100% detection of RNA extracted from specimens with ≥0.5 SARS-CoV-2 RNA copies/µL, with 100% specificity in specimens positive for other respiratory pathogens. VTM is non-ideal for Harmony system, yet extraction-free analysis (n=29) had 95% success in specimens with ≥1 RNA copies/µL. Usability testing performed first-time by healthcare workers showed 95% accuracy.
Teaser A novel four-plexed RT-LAMP test kit operated by health workers can provide faster and more sensitive results than lab tests.
Competing Interest Statement
E.K., N.P., Q.W., I.H., D. L., R. A., M.P.,and B.R.L. are inventors on one or more patent applications related to this work. E.K., N.P., Q.W., I.H., D. L., R. A., M.P.,A.K.O, C.B., and B.R.L. hold equity in a startup company that licenses this technology.
Funding Statement
This work was supported by the Seattle Flu Study (funded by Gates Ventures) and the National Institutes of Health (R01AI140845; 5R61AI140460-03). We thank the Washington Entrepreneurial Research Evaluation and Commercialization HUB program (WE-REACH, U01 HL152401) and their matching grant partners for partly supporting reagents, supplies, and personnel. I.T.H. was supported in part by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number T32GM008268. This work does not reflect the views of the funders. The funders were not involved in the design of the study, and funders do not have any ownership over the management and conduct of the study, the data, or the rights to publish.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
These specimens were collected with informed consent as part of the Seattle Flu Study, approved by the Institutional Review Board at the University of Washington (IRB: STUDY0006181). The Harmony usability study was approved by the Institutional Review Board at the University of Washington (IRB: STUDY00010884), and informed consent was provided by participants.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data and materials availability: All data are presented in the main text and supplementary information.
